Hepu Pharmaceuticals is an innovative drug developer in the field of viral hepatitis. The company focuses on the research and development of original new drugs, and has the overall research and development capabilities from new drug concept design, preclinical research, pilot research to clinical research and new drug mass production. At present, the research and development of hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia, including hepalatide, are under development. Recently, Hepu Pharmaceuticals completed the Pre-B round of financing, which was exclusively invested by Shanghai Zhangke Lingyi Fund. Hepu Pharmaceuticals has received a cumulative investment of more than 100 million yuan. The completion of this round of financing marks that the company has entered a new stage of development.
This article is reproduced from: https://www.itjuzi.com/investevent/13319093
This site is for inclusion only, and the copyright belongs to the original author.